Roche’s Breast Cancer Drug Falls Short In Phase 3 Study
Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined…
Roche’s Breast Cancer Drug Falls Short In Phase 3 Study
Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…
Roche’s giredestrant cuts recurrence, death risk 30% in early breast cancer
Roche (OTCQX: RHHBY) announced positive phase III lidERA results showing investigational oral SERD…